Breton2 mg

Breton is a selective, long-acting beta-2 adrenergic receptor agonist used as a bronchodilator. Its established and guideline-supported uses include:

• Bronchial asthma: Maintenance/prophylactic treatment to control and prevent bronchospasm as part of a regular asthma-management regimen, used together with appropriate anti-inflammatory controller therapy (e.g., inhaled corticosteroids) rather than as monotherapy in persistent asthma, per current asthma-management guidelines.
• Chronic bronchitis and asthmatic bronchitis: Symptomatic relief of bronchospasm associated with chronic obstructive airway conditions.
• Pulmonary emphysema: Adjunct bronchodilator therapy for bronchospasm associated with emphysema.

Breton is intended for regular, scheduled maintenance dosing and is not a fast-acting rescue medicine; a short-acting bronchodilator should always be available separately for sudden or acute symptoms.

Each formulation of Tulobuterol Hydrochloride contains tulobuterol hydrochloride as the active pharmaceutical ingredient. It is available locally as tablets (2 mg) and as an oral syrup (1 mg/5 mL), along with the usual pharmaceutical excipients required for tablet or syrup formulation. In some other markets, Tulobuterol Hydrochloride is also formulated as a transdermal patch for once-daily application.

Breton is a synthetic, selective beta-2 adrenoceptor agonist belonging to the sympathomimetic amine class of bronchodilators. It is chemically related to other beta-2 agonists but is notable for its relatively long duration of bronchodilator action compared with short-acting agents such as salbutamol.

Clinically, Breton is used for the prophylaxis and control of bronchospasm in chronic respiratory conditions such as bronchial asthma, chronic bronchitis, asthmatic bronchitis, and pulmonary emphysema. Oral onset of bronchodilator effect typically occurs within about 30 minutes, with an extended duration of action that supports twice-daily oral dosing. In addition to oral tablet and syrup forms, Breton is marketed in some countries as a transdermal patch that provides sustained, roughly 24-hour bronchodilation from a single daily application; this patch formulation has a delayed onset of action and is not suitable for treating acute bronchospasm.

Breton belongs to the therapeutic class of long-acting selective beta-2 adrenergic agonist (LABA) bronchodilators, used in the management of obstructive airway diseases.

Tulobuterol Hydrochloride selectively stimulates beta-2 adrenergic receptors located on bronchial smooth muscle. This activates the enzyme adenylate cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP), which in turn causes relaxation of bronchial smooth muscle and bronchodilation. Its relative beta-2 selectivity is associated with fewer cardiac (beta-1 mediated) effects compared with non-selective sympathomimetic bronchodilators, although cardiovascular stimulation can still occur, particularly at higher doses.

After oral administration, Tulobuterol Hydrochloride is absorbed from the gastrointestinal tract, undergoes hepatic metabolism, and is eliminated predominantly via the kidneys, with a duration of action that supports twice-daily dosing. Where a transdermal patch formulation of Tulobuterol Hydrochloride is available, the drug is absorbed continuously through the skin, producing sustained plasma concentrations and bronchodilation over approximately 24 hours; because absorption is gradual, the onset of effect from the patch is delayed compared with oral or inhaled rescue bronchodilators.

Breton tablets and syrup are taken orally, generally with or without food, at evenly spaced intervals (approximately every 12 hours) as directed by the physician. Swallow tablets whole; measure syrup doses accurately using a proper measuring device. Where a patch formulation of Breton is used, apply it to clean, dry, hairless skin on the chest, back, or upper arm, removing the previous patch first, and rotate application sites to avoid irritation. Do not apply direct heat (heating pads, saunas, electric blankets) over a patch, as this can increase drug absorption.

Breton has the following clinically significant drug interactions:

• Digoxin: Concurrent use may increase the risk of cardiac arrhythmias.
• Xanthines (e.g., theophylline), corticosteroids, and diuretics: Concomitant use increases the risk of hypokalemia, which may increase susceptibility to cardiac arrhythmias.
• Other beta-2 agonists or sympathomimetic bronchodilators (including other LABA-containing products): Concurrent use should be avoided as it increases the risk of additive cardiovascular and beta-agonist toxicity (tachycardia, tremor, arrhythmia).
• Beta-blockers: May antagonize the bronchodilator effect of Breton and should generally be avoided in patients with reactive airway disease.
• Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: May potentiate the cardiovascular effects of Breton; use with caution.

Common and clinically important side effects of Breton include:

• Common: Fine tremor (especially of the hands), palpitations, tachycardia, headache, nervousness/CNS stimulation, insomnia.
• Cardiovascular: Hypertension, angina, and, rarely, arrhythmias, particularly with overuse or in predisposed patients.
• Gastrointestinal: Nausea, vomiting.
• Metabolic: Hypokalemia (see Precautions & Warnings), especially with concurrent diuretics or corticosteroids, or in acute severe exacerbations.
• Other: Vertigo/dizziness; with the patch formulation, application-site skin irritation or redness may occur.

Tremor is dose-related and tends to diminish with continued use. Patients should seek medical advice if side effects are severe or persistent.

The safety of Breton during pregnancy has not been well established. As with other beta-2 agonists, it should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should always be consulted before use.

It is not known whether Breton is excreted in human breast milk or what effects this might have on a nursing infant. Caution is advised, and a physician should be consulted before use of Breton during breastfeeding, weighing the benefits of treatment against potential risk to the infant.

Breton should be used with caution in the following situations:

• Cardiovascular disease: Including coronary insufficiency, arrhythmias, and hypertension, because beta-2 agonists can cause tachycardia, palpitations, and rarely, more serious cardiovascular effects.
• Hyperthyroidism: Sympathomimetic effects may be exaggerated.
• Diabetes mellitus: Beta-agonists may affect glucose control.
• Seizure disorders: Use with caution due to CNS-stimulant effects.
• Hypokalemia risk: Particularly with concurrent diuretics, corticosteroids, or in acute severe asthma exacerbations; monitor potassium levels where clinically indicated.
• Renal or hepatic impairment: Dose adjustment and closer monitoring may be needed since Breton is metabolized in the liver and eliminated by the kidneys.
• Not a rescue therapy: Do not use Breton for acute bronchospasm; always keep a fast-acting rescue bronchodilator available.
• LABA-monotherapy caution: In persistent asthma, Breton should be used together with an appropriate anti-inflammatory controller (e.g., inhaled corticosteroid) rather than alone, in line with current asthma-management guidelines.
• Avoid concurrent LABA use: Do not use Breton together with other long-acting beta-agonist-containing products, due to the risk of additive toxicity.
• Patch-specific precautions (where applicable): Rotate application sites to reduce skin irritation; always remove the old patch before applying a new one to avoid double-dosing from overlapping patches; avoid exposing the patch to direct heat sources (heating pads, saunas, electric blankets), as this can increase the rate of drug absorption.

Overdose with Breton may cause exaggerated beta-agonist effects, including marked tachycardia, palpitations, tremor, arrhythmias, chest pain, hypertension or hypotension, hypokalemia, seizures, and CNS stimulation or, less commonly, CNS depression. If overdose of Breton is suspected, seek immediate medical attention or contact a poison control center right away. Treatment is supportive and should be provided under medical supervision; do not attempt specific home treatment.

Store Breton at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Start Breton at the lower end of the dosing range (e.g., 1 mg twice daily orally) due to greater sensitivity to sympathomimetic cardiovascular effects, and increase cautiously if needed.

Renal impairment: Use with caution and consider dose reduction, as Breton is eliminated mainly via the kidneys.

Hepatic impairment: Use with caution and consider dose adjustment, as Breton undergoes hepatic metabolism.

Cardiovascular disease, hyperthyroidism, diabetes mellitus, seizure disorders: See Precautions & Warnings for detailed cautions regarding use of Breton in these populations.

Breton is generally used as a long-term maintenance therapy for chronic conditions such as asthma, chronic bronchitis, and emphysema-related bronchospasm, for as long as the treating physician determines it is needed. Treatment should be reviewed periodically by the physician to reassess ongoing need, dose, and concurrent controller therapy, and should not be stopped or altered abruptly without medical advice.

Tulobuterol Hydrochloride belongs to the drug class of selective, long-acting beta-2 adrenergic receptor agonists (sympathomimetic bronchodilators).

Tulobuterol Hydrochloride acts by selectively stimulating beta-2 adrenergic receptors on bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP (cAMP), which produces relaxation of bronchial smooth muscle and bronchodilation, thereby relieving and preventing bronchospasm.

Breton oral syrup (1 mg/5 mL) may be used in children as young as 1 year for bronchospasm associated with asthma or bronchitis, with dosing individualized by age (approximately 2.5-5 mL twice daily for ages 1-6 years, 5-10 mL twice daily for ages 6-12 years, and 10-20 mL twice daily above 12 years, or approximately 40-80 mcg/kg/day in two divided doses), under a physician's supervision. Safety and efficacy of Breton in infants under 1 year of age have not been established. As in adults, Breton should not be relied upon as a rescue therapy for acute bronchospasm in children.